LON:RENE - ReNeuron Group Stock Price, News & Analysis

GBX 205
+10.00 (+5.13 %)
(As of 09/16/2019 04:00 PM ET)
Today's Range
197.10
Now: GBX 205
210
50-Day Range
190
MA: GBX 215.50
240
52-Week Range
29.50
Now: GBX 205
342
Volume134,683 shs
Average Volume28,700 shs
Market Capitalization£65.26 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia. Read More…

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-38198400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£2.72 million
Cash FlowGBX 71.24 per share
Book ValueGBX 74 per share

Profitability

Miscellaneous

Employees62
Market Cap£65.26 million
Next Earnings DateN/A
OptionableNot Optionable

Receive RENE News and Ratings via Email

Sign-up to receive the latest news and ratings for RENE and its competitors with MarketBeat's FREE daily newsletter.


ReNeuron Group (LON:RENE) Frequently Asked Questions

What is ReNeuron Group's stock symbol?

ReNeuron Group trades on the London Stock Exchange (LON) under the ticker symbol "RENE."

How were ReNeuron Group's earnings last quarter?

ReNeuron Group Plc (LON:RENE) announced its earnings results on Thursday, July, 11th. The company reported ($45.20) EPS for the quarter, topping the consensus estimate of ($49.80) by $4.60. View ReNeuron Group's Earnings History.

Has ReNeuron Group been receiving favorable news coverage?

Media coverage about RENE stock has been trending somewhat positive recently, according to InfoTrie. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. ReNeuron Group earned a news sentiment score of 0.9 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for ReNeuron Group.

Who are some of ReNeuron Group's key competitors?

What other stocks do shareholders of ReNeuron Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ReNeuron Group investors own include International Road Dynamics (IRD), Sareum (SAR), ValiRx (VAL), Independent Oil & Gas (IOG), Dignity (DTY), Tri-star Resources (TSTR), Sirius Minerals (SXX), Collagen Solutions (COS), RenovaCare (RCAR) and ReNeuron Group (RNUGF).

Who are ReNeuron Group's key executives?

ReNeuron Group's management team includes the folowing people:
  • Mr. Olav Hellebø, CEO & Director (Age 54)
  • Mr. Michael E. Hunt, CFO, Sec. & Exec. Director (Age 56)
  • Dr. John David Sinden BA, MA, Ph.D., Founder & Chief Scientific Officer (Age 68)
  • Dr. Randolph Corteling, Head of Research
  • Mr. Shaun Stapleton BSc (Hons) MTOPRA, Head of Regulatory Affairs

How do I buy shares of ReNeuron Group?

Shares of RENE and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ReNeuron Group's stock price today?

One share of RENE stock can currently be purchased for approximately GBX 205.

How big of a company is ReNeuron Group?

ReNeuron Group has a market capitalization of £65.26 million and generates £2.72 million in revenue each year. ReNeuron Group employs 62 workers across the globe.View Additional Information About ReNeuron Group.

What is ReNeuron Group's official website?

The official website for ReNeuron Group is http://www.reneuron.com/.

How can I contact ReNeuron Group?

ReNeuron Group's mailing address is Pencoed Business Park, BRIDGEND, CF35 5HY, United Kingdom. The company can be reached via phone at +44-20-38198400.


MarketBeat Community Rating for ReNeuron Group (LON RENE)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  170 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  277
MarketBeat's community ratings are surveys of what our community members think about ReNeuron Group and other stocks. Vote "Outperform" if you believe RENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RENE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel